Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ubamatamab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Ubamatamab - Regeneron Pharmaceuticals

Alternative Names: Anti MUC16-CD3 antibody; Anti-MUC16/CD3-BiTE-antibody-REGN4018; antiMUC16-antiCD3-monoclonal-antibodies; Bispecific-T-cell-engager-antibody-REGN-4018; BiTE-antibody-REGN-4018; MUC16xCD3-bispecific-monoclonal-antibodies; REGN4018

Latest Information Update: 11 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer; Renal cancer; Sarcoma
  • Phase I/II Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 04 Sep 2025 Regeneron Pharmaceuticals plans a phase II trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) (IV) in January 2026 (NCT07154290)
  • 29 Jan 2025 Regeneron Pharmaceuticals plans a phase II trial for Ovarian Cancer () in (Country) (Ref), (NCT ref)
  • 22 Jan 2025 Regeneron Pharmaceuticals plans a phase II trial for Ovarian cancer, Peritoneal cancer and Fallopian tube cancer (Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) in May 2025 (NCT06787612)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top